"PlantForm has the potential to be a leader in the expanding market for biosimilar antibody drugs. It has proprietary technology capable of making complex human antibodies quickly and inexpensively. It also has a management team with the industry experience necessary for success." John Connolly,
York Medtech Partners
Industry news Amgen 'primed for acquisitions'
U.S.-based Amgen is on the lookout for quality pharma companies at the right price, the Financial Times
reports. Pfizer ramps up biologics
Pfizer is partnering with smaller companies on second-generation biologics for a market that could grow to $187B by 2014, the Wall Street Journal
reports. Europe cuts drug spending
European governments are slashing spending on pharmaceuticals to reel in budget deficits, the Wall Street Journal
Don Stewart, PhD
President & CEO Ron Hosking, CA
Chief Financial Officer Chris Hall, PhD
Chief Scientific Officer
Board of Directors Mark Goldberg, PhD (Chair)
Founder & Director R&D
GlobalTox, a division of MTE Consultants Inc.
CEO, Viron Therapeutics Warren Whitehead
former CFO, Arius Research Chris Hall, PhD
CSO, PlantForm Corp. Don Stewart, PhD
President & CEO, PlantForm Corp.